MedTrace Logo

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

NCT03906331 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2025-01-17

No results posted yet for this study

Summary

Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Conditions

Interventions

DRUG

Selpercatinib

Open-label expanded access

Sponsors & Collaborators

Principal Investigators

  • Contact Lilly at 1-800-LillyRx (1-800-545-5979) · Eli Lilly and Company

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Australia
  • France
  • Germany
  • Hong Kong
  • Israel
  • Italy
  • Japan
  • New Zealand
  • Poland
  • Singapore
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03906331 on ClinicalTrials.gov